R&D | January 14, 2026
Codexis teams up with Axolabs to advance enzymatic RNA manufacturing
The collaboration gives Axolabs access to Codexis’ innovative RNA manufacturing technology
The collaboration gives Axolabs access to Codexis’ innovative RNA manufacturing technology
The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of June 10, 2026
Projects selected for advancement will move forward through the Harvard Office of Technology Development’s processes for sponsored research agreements
The trial supports the potential for another chemotherapy backbone option that may be paired with encorafenib plus cetuximab in this patient population
CHOMax integrates cell line development, process development, analytics, and GMP manufacturing under robust quality processes
MH002, a rationally designed live microbial consortium, combines six well-characterized commensal strains to target disease-specific mechanisms
The grant will fund ten new J.MD projects over the next three years, targeting multiple global health threats
The therapy is mutation-agnostic and aims to overcome limitations of existing EGFR-targeting drugs by concentrating degradation in tumors while sparing healthy tissue
Supports production of AbbVie's current and next-generation immunology and neuroscience medicines
The partnership aims to develop a first-in-class broad-spectrum antifungal to combat life-threatening invasive infections
Subscribe To Our Newsletter & Stay Updated
